Search

peripheral blood smear. After viral, infectious, rheumatologic tests were normal, we applied bone marrow aspiration and biopsy and it was normocellular. We determined PNH clon at the flaer test. Then, we started to eculizumab therapy. He has been treated with eculizumab for two years. And also he has been treated 1200 mg eculizumab every 12 days for twenty months. In the last hemogram wbc: 3300 mm3, hgb: 6.2 g/dl, plt: 2000 mm3. He had a lot of transfusions during two years. He has no donor for allogeneic stem cell transplantation. We are still looking for unrelated donor for him. Conclusion: Eculizumab therapy has been shown to reduce the need for blood transfusion in patients with PNH.

Background: Pomegranate is also named Punica granatum native to Asia which contains a number of bioactive compounds such as phenolics, flavonoids ellagitannins and minerals. Previous studies have reported the anticarcinogenic effects of Pomegranate via inducing apoptosis and inhibition of cell proliferation in various cancer types. Purpose: In this study, we aimed to identify the cytotoxic and apoptotic effects of pomegranate extracts on U266 multiple myeloma cells. Methods: The cytotoxic effects of P. granatum leave, stem and flower on U266 cells were conducted via MTT cell proliferation assay. Then, apoptotic effects of P. granatum leave, stem and flower extracts on U266 cells were tested by loss of mitochondrial membrane potential and location of phosphotidylserine. Cell cycle analysis by flow cytometry was also performed to obtain cell populations in different phases by flow cytometry. Results: P. granatum extracts inhibited proliferation on U266 cells in a dose-dependent manner. We determined 87-, 88-, and 82% decreases in proliferation of U266 cells exposed to 500 μg/ml P. granatum leave, 500 μg/ml P.granatum stem and 100μg/ml P. granatum flower extracts for 72 hours, respectively, as compared to untreated cells. Annexin-V analysis revealed that there were 13-, 17-, and 19 fold increases in apoptotic cell population of U266 exposed to 500-, 750-, and 1000 μg/ml P. granatum leave extract, 16and 27 fold increases in apoptotic cell population exposed to 750-, and 1000 μg/ml P. granatum stem extract whereas 1.6and 3.5 fold increases in apoptotic cells exposed to 50 and 100 μg/ml P. granatum flower extract for 72 hours, respectively, as compared to control group cells. Loss of mitochondrial membrane potential analyses also confirmed apoptosis results. Summary/conclusion: These results documented cytotoxic and apoptotic effects of P. granatum extracts on human U266 multiple myeloma cells. Pomegranate induced apoptosis through deformation of mitochondrial membrane potential and increasing cell cycle arrests.

Multiple myeloma is of great concern since existing therapies are unable to cure this clinical condition. Alternative therapeutic approaches are mandatory, and the use of plant extracts is considered interesting. Punica granatum and its derived products were suggested as potential anticancer agents due to the presence of bioactive compounds. Thus, polypenolic-rich extracts of the non-edible parts of P. granatum were investigated for their antiproliferative and apoptotic effects on U266 multiple myeloma cells. We demonstrated that there were dose-dependent decreases in the proliferation of U266 cells in response to P. granatum extracts. Also, exposure to the extracts triggered apoptosis with significant increases in loss of mitochondrial membrane potential in U266 cells exposed to the leaves and stem extracts, while the flower extract resulted in slight increases in loss of MMP. These results were confirmed by Annexin-V analysis. These results documented the cytotoxic and apoptotic effects of P. granatum extracts on human U266 multiple myeloma cells via disruption of mitochondrial membrane potential and increasing cell cycle arrest. The data suggest that the extracts can be envisaged in cancer chemoprevention and call for further exploration into the potential application of these plant parts.